Two Sigma Securities’s Agile Therapeutics AGRX Stock Holding History

Two Sigma Securities’s Portfolio AGRX Stock Details AGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-397	Closed	-$4.44K	–	3558
2023 Q1	$4.44K	Buy	397 +132	+50%	+$1.69K	﹤0.01%	2533
2022 Q4	$3.01K	Buy	+265	New	+$3.08K	﹤0.01%	2491
2022 Q2	–	Sell	-9	Closed	-$4K	–	2986
2022 Q1	$4K	Buy	+9	New	+$5.75K	﹤0.01%	2068
2018 Q3	–	Sell	-10	Closed	-$10K	–	3138
2018 Q2	$10K	Buy	+10	New	+$35.1K	﹤0.01%	2587

Other funds holding AGRX

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Two Sigma Securities's AGRX Position: Q2 2023 in Review

Two Sigma Securities sold out of Agile Therapeutics (AGRX) in Q2 2023, closing a stake of 397 shares — an estimated $4.44K sold.

Two Sigma Securities first reported a position in AGRX in Q2 2018 and held it in 4 quarters. The position peaked at $10K in Q2 2018. 16 funds tracked by Wall St. Rank hold AGRX as of Q2 2023.

Two Sigma Securities reported no remaining Agile Therapeutics position as of Q2 2023 after selling out during the quarter.
Two Sigma Securities sold 397 Agile Therapeutics shares in Q2 2023, an estimated $4.44K.
Two Sigma Securities first reported a position in Agile Therapeutics in Q2 2018 and held it in 4 quarters.
Two Sigma Securities's Agile Therapeutics position peaked at $10K in Q2 2018.
16 funds tracked by Wall St. Rank held Agile Therapeutics as of Q2 2023.

Based on Two Sigma Securities's 13F filing for Q2 2023, filed 14 Aug 2023.